Overview

N-acetylcysteine in Liver Transplantation

Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
N-acetylcysteine (NAC) is used to treat Tylenol toxicity. NAC is a rich source of the sulfhydryl group (SH) which is important for replenishing the body's glutathione stores. Glutathione acts as a free radical scavenger, to decrease the damage that would be caused by those toxic radicals. Patients who undergo orthotopic liver transplantation (OLT) have a high incidence of post-operative renal dysfunction. The most common etiology of post-operative renal dysfunction is related to high levels of toxic free radicals. Free radicals may contribute to primary liver graft failure or delayed liver graft function. Specific Aims & Objectives: The primary objective of this study is to evaluate the efficacy of NAC in improving liver graft performance and lowering the incidence of post-operative renal dysfunction. The secondary objectives are to investigate the effect of NAC on endogenous glutathione body stores and its effect on FK506 induced toxicity.
Phase:
N/A
Details
Lead Sponsor:
Ibtesam Hilmi
University of Pittsburgh
Treatments:
Acetylcysteine
Cystatins
N-monoacetylcystine